Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “1×10\^8\~2×10\^9 cells will be infused intravenously for 4 times.”In the company’s words, NCT06256055 on ClinicalTrials.gov
- Tested for
- Malignant Mesothelioma, Colorectal Cancer, Bile Duct Cancer, Rectal Cancer, Ovary Cancer, Pancreatic Cancer, Breast Cancer Female
- Main trialPhase 1
- “This is a first-in-human, single-arm, open-label, dose escalation clinical study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics, immunogenicity and preliminary efficacy of UCMYM802 (Circular mRNA encoding Anti-Mesothelin CAR-T) injection in patients with Mesothelin-positive advanced malignant solid tumors.”In the company’s words, NCT06256055 on ClinicalTrials.gov
Other drugs for Malignant Mesothelioma
- VT3989Vivace Therapeutics, Inc · Phase 3
- VolrustomigAstraZeneca · Phase 3
- EB-MF-CAR-NK-01Beijing Biotech · Phase 1/2
- ISM6331InSilico Medicine Hong Kong Limited · Phase 1/2
- Alintegimod7 Hills Pharma, LLC · Phase 1/2
- TYK-01054TYK Medicines · Phase 1/2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Unknown | Mar 2025 | Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026